Business Context and Reporting Period
This Form 8-K, dated December 17, 2019, reports that Zafgen, Inc. (trading symbol ZFGN) entered into an Agreement and Plan of Merger with Chondrial Therapeutics, Inc. Upon closing, Zafgen will be renamed Larimar Therapeutics, Inc. The transaction involves a reverse stock split to maintain Nasdaq listing requirements and a change in corporate name.
Key Financial Metrics and Transaction Terms
- Ownership Structure: Post-merger, former Chondrial securityholders are expected to own approximately 60% of the combined company on a fully-diluted basis, while existing Zafgen securityholders will own approximately 40%.
- Termination Fees: The agreement stipulates a termination fee of $3,375,000 payable by either party under specified circumstances, plus reimbursement of third-party expenses up to $350,000.
- Cash Conditions: Closing is subject to Zafgen maintaining a minimum net cash threshold of $30,000,000 and Chondrial maintaining not less than zero net cash.
- Stockholder Support: Zafgen directors, officers, and its largest stockholder (controlling ~9.7% of shares) have entered into support agreements to vote in favor of the merger.
- Lock-up Agreements: Key insiders from both companies and major stockholders are subject to a 180-day lock-up on shares received in the merger.
Material Changes and Operational Updates
The primary material change is the proposed merger, which will result in a change of control and a shift in the company's strategic focus toward Chondrial's biotechnology pipeline. Concurrently, on December 18, 2019, Chondrial announced the dosing of the first patients in a Phase 1 clinical trial for CTI-1601, a treatment for Friedreich's Ataxia.
Guidance, Risks, and Contingencies
- Closing Conditions: The merger is contingent upon stockholder approvals from both Zafgen and Chondrial, the filing of a proxy statement, and the satisfaction of minimum net cash thresholds.
- Ownership Adjustments: The final ownership percentages (60/40 split) are subject to adjustment based on Zafgen's net cash levels at closing.
- Board Composition: The post-merger board will include Peter Barrett, Carole Ben-Maimon, Thomas Daniel, Thomas Hamilton, Jonathan Leff, Frank Thomas, and one designee from Deerfield Management.
- Risks: Risks include failure to obtain stockholder approval, inability to meet cash thresholds, delays in regulatory approvals, and potential adverse market reactions. The filing explicitly disclaims any obligation to update forward-looking statements.
Investor Verification Checklist
- Verify the upcoming proxy statement for detailed financial data and voting procedures.
- Confirm Zafgen's current net cash position to assess the likelihood of meeting the $30 million closing threshold.
- Review the specific terms of the reverse stock split ratio once determined by the companies.
- Monitor the progress of Chondrial's Phase 1 clinical trial for CTI-1601 as a key value driver for the combined entity.
- Check for any subsequent filings regarding the status of the "no-shop" provision and potential alternative acquisition proposals.